Trends and issues in oncology costs

Expert Review of Pharmacoeconomics and Outcomes Research

Volumn 14, Issue 1, 2014, Pages 35-44

  Scalo, Julieta F ^a   Rascati, Karen L ^a  

^a UNIVERSITY OF TEXAS AT AUSTIN   (United States)

Author keywords

Cancer; Chemotherapy; Clinical pathway; Cost effectiveness research; Disease management; Oncologic; Oncology; Pay for performance

Indexed keywords

BEVACIZUMAB; CETUXIMAB; ERIBULIN; ERLOTINIB; IMATINIB; IPILIMUMAB; IRINOTECAN; RITUXIMAB; SIPULEUCEL T; TRASTUZUMAB;

BREAST CANCER; BREATHING DISORDER; CANCER CHEMOTHERAPY; CANCER INCIDENCE; CHRONIC MYELOID LEUKEMIA; COLORECTAL CANCER; COMPARATIVE EFFECTIVENESS; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DIARRHEA; DRUG COST; FOLLICULAR LYMPHOMA; HEALTH CARE COST; HEALTH CARE DELIVERY; HEALTH CARE POLICY; HEALTH CARE QUALITY; HUMAN; LUNG CANCER; MANAGED CARE; MEDICARE; MELANOMA; ONCOLOGY; OUTCOME ASSESSMENT; PANCREAS CANCER; PROSTATE CANCER; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; RASH; REIMBURSEMENT; REVIEW; UNITED STATES; WELLBEING;

COST-BENEFIT ANALYSIS; DELIVERY OF HEALTH CARE; HEALTH CARE COSTS; HUMANS; NEOPLASMS; PATIENT PROTECTION AND AFFORDABLE CARE ACT; QUALITY OF HEALTH CARE; QUALITY OF LIFE; UNITED STATES;

EID: 84893120163     PISSN: 14737167     EISSN: 17448379     Source Type: Journal    
DOI: 10.1586/14737167.2014.864561     Document Type: Review

References (88)

1. Keehan SP, Sisko AM, Truffer CJ et al. National health spending projections through 2020: Economic recovery and reform drive faster spending growth. Health Aff. 30(8), 1594-1605 (2011
2. Mariotto AB, Yabroff KR, Shao Y, Feuer EJ, Brown ML. Projections of the cost of cancer care in the United States: 2010-2020. J. Natl Cancer Inst. 103(2), 117-128 (2011
3. IOM (Institute of Medicine). Delivering high-quality cancer care: Charting a new course for a system in crisis. The National Academies Press, Washington, DC, USA
4. Tangka FK, Trogdon JG, Richardson LC, Howard D, Sabatino SA, Finkelstein EA. Cancer treatment cost in the United States: Has the burden shifted over timëCancer 116(14), 3477-3484 (2010
5. Short PF, Moran JR, Punekar R. Medical expenditures of adult cancer survivors aged <65 years in the United States. Cancer 117(12), 2791-2800 (2011
6. Bodenheimer T, Berenson R. The primary care-specialty income gap: Why it matters. Ann. Intern. Med. 146(4), 301-306 (2007
7. Twombly R. Medicare cost containment strategy targets several oncology drugs. J. Natl Cancer Inst. 96(17), 1268-1270 (2004
8. Benson LR. Reimbursing cancer care: Medicare policies challenged. J. Natl Cancer Inst. 93(21), 1595-1597 (2001
9. Warren JL, Yabroff KR, Meekins A, Topor M, Lamont EB, Brown ML. Evaluation of trends in the cost of initial cancer treatment. J. Natl Cancer Inst. 100(12), 888-897 (2008
10. Schrag D. The price tag on progress - chemotherapy for colorectal cancer. N. Engl. J. Med. 351(4), 317-319 (2004
11. Meropol NJ, Schulman KA. Cost of cancer care: Issues and implications. J. Clin. Oncol. 25(2), 180-186 (2007
12. Fojo T, Grady C. How much is life worth: Cetuximab, non-small cell lung cancer, and the $440 billion question. J. Natl Cancer Inst. 101(15), 1044-1048 (2009
13. Smith TJ, Hillner BE. Concrete options and ideas for increasing value in oncology care: The view from one trench. Oncologist 15(Suppl. 1), 65-72 (2010
14. Hillner BE, Smith TJ. Efficacy does not necessarily translate to cost effectiveness: A case study in the challenges associated with 21st-century cancer drug pricing. J. Clin. Oncol. 27(13), 2111-2113 (2009
15. Doloresco F, Fominaya C, Schumock G. Projecting future drug expenditures - 2011. Am. J. Health Syst. Pharm. 68, e1-e12 (2011
16. Hoffman JM, Li E, Doloresco F et al. Projecting future drug expenditures - 2012. Am. J. Health Syst. Pharm. 69(5), 405-421 (2012
17. Aitken M, Kleinrock M. Declining Medicine Use and Costs: For Better or WorsëIMS Institute for Healthcare Informatics, Parsippany, NJ, USA
18. Hoffman JM, Li E, Doloresco F et al. Projecting future drug expenditures in US nonfederal hospitals and clinics - 2013. Am. J. Health Syst. Pharm. 70, 525-539 (2013
19. Chambers JD, Neumann PJ. Listening to Provenge - What a costly cancer treatment says about future Medicare policy. N. Engl. J. Med. 364(18), 1687-1689 (2011
20. Sledge GW. Musings of a cancer doctor: The cost of drugs. Oncol. Times 33(16), 32 (2011
21. Ginsburg G, Konstance R, Allsbrook J, Schulman K. Implications of pharmacogenomics for drug development and clinical practice. Arch. Intern. Med. 165(20), 2331-2336 (2005
22. Gavel S. The oncology pipeline: Maturing, competitive, and growing? Oncol. Bus. Rev. 14-16 (2008
23. Conti RM, Bernstein AC, Villaflor VM, Schilsky RL, Rosenthal MB, Bach PB. Prevalence of off-label use and spending in 2010 among patent-protected chemotherapies in a population-based cohort of medical oncologists. J. Clin. Oncol. 31(9), 1134-1139 (2013
24. Siegel R, Ward E, Brawley O, Jemal A. Cancer statistics, 2011. CA Cancer J. Clin. 61, 212-236 (2009
25. Silberman G, Downs CG. Recent legislation changes the economics of cancer care. ONS News 20(7), 9 (2005
26. Iglehart J. Medicare and drug pricing. N. Engl. J. Med. 348(16), 1590-1597 (2003
27. Bailes JS, Coleman T. The new Medicare bill: Far-reaching effects on cancer treatment. Clin. Adv. Hematol. Oncol. 2(5), 292-294 (2004
28. Malin JL, Weeks JC, Potosky AL, Hornbrook MC, Keating NL. Medical oncologists' perceptions of financial incentives in cancer care. J. Clin. Oncol. 31(5), 530-535 (2013
29. Potetz L, DeWilde LF. Cancer and Medicare: A Chartbook. American Cancer Society Cancer Action Network, Washington, DC, USA
30. Jacobson M, ÓMalley AJ, Earle CC, Pakes J, Gaccione P, Newhouse JP Does reimbursement influence chemotherapy treatment for cancer patients? Health Aff. 25(2), 437-443 (2006
31. Shahinian VB, Kuo Y-F, Gilbert SM. Reimbursement policy and androgen-deprivation therapy for prostate cancer. N. Engl. J. Med. 363(19), 1822-1832 (2010
32. Jacobson M, Earle CC, Price M, Newhouse JP. How medicarés payment cuts for cancer chemotherapy drugs changed patterns of treatment. Health Aff. 29(7), 1391-1399 (2010
33. Grumbach K, Osmond D, Vranizan K. Primary care physicians' experience of financial incentives in managed-care systems. N. Engl. J. Med. 339(21), 1516-1521 (1998
34. McGivney WT, Mullen J. Cancer and managed care in the 21st century. Am. J. Manag. Care 11(17 Suppl.), S509-S521 (2005
35. Timmermans S, Mauck A. The promises and pitfalls of evidence-based medicine. Health Aff. 24(1), 18-28 (2005
36. Draper D, Hurley R, Lesser C, Strunk B. The changing face of managed care. Health Aff. 21(1), 11-23 (2002
37. Garber AM. Evidence-based guidelines as a foundation for performance incentives. Health Aff. 24(1), 174-179 (2005
38. Danielson E, Demartino J, Mullen JA. Managed care & medical oncology: The focus is on value. J. Natl Compr. Canc. Netw. 8 (Suppl. 7), S28-S37 (2010
39. Dunn JD, Ellis PG, Fox JL et al. Payer and provider collaborations that improve quality outcomes in oncology. Manag. Care. 19(11), 35-40, 42 (2010
40. Neubauer MA, Hoverman JR, Kolodziej M et al. Cost effectiveness of evidence-based treatment guidelines for the treatment of non-small-cell lung cancer in the community setting. J. Oncol. Pract. 6(1), 12-18 (2010
41. Hoverman JR, Cartwright TH, Patt DA et al. Pathways, outcomes, and costs in colon cancer: Retrospective evaluations in two distinct databases. J. Oncol. Pract. 7(3S), 52s-59s (2011
42. Eichler H-G, Abadie E, Breckenridge A et al. Bridging the efficacy-effectiveness gap: A regulator's perspective on addressing variability of drug response. Nat. Rev. Drug Discov. 10(7), 495-506 (2011
43. Newcomer L. Cost of new oncology drugs. Clin. Adv. Hematol. Oncol. 8(5), 313-314 (2010
44. Holcombe D. Oncology management programs for payers and physicians: Evaluating current models and diagnosing successful strategies for payers and physicians. J. Oncol. Pract. 7(3 Suppl.), e46s-e49s (2011
45. Blackmore CC, Mecklenburg RS, Kaplan GS. At Virginia Mason, collaboration among providers, employers, and health plans to transform care cut costs and improved quality. Health Aff. 30(9), 1680-1687 (2011
46. Regan M. Cancer and disease management: Indications for action. Dis. Manag. Health Out. 6(4), 203-211 (1999
47. Ellrodt G, Cook DJ, Lee J, Cho M, Hunt D, Weingarten S. Evidence-based disease management. JAMA 278(20), 1687-1692 (1997
48. Hunter DJ, Fairfield G. Managed care: Disease management. BMJ 315(7099), 50-53 (1997
49. Villagra V. Strategies to control costs and quality: A focus on outcomes research for disease management. Med. Care 42(4), 24-30 (2004
50. Kash KM, Sharma S, Goldfarb NI. Is disease management right for oncology? Popul. Health Manag. 12(6), 337-343 (2009
51. Pierce D. Managing managed care. Oncology Issues November/December, 32-35 (2005
52. Fetterolf DE, Terry R. Oncology disease management. Dis. Manag. 10(1), 30-36 (2007
53. Eijkenaar F. Key issues in the design of pay for performance programs. Eur. J. Health Econ. 14(1), 117-131 (2013
54. Chen JY, Kang N, Juarez DT, Hodges KA, Chung RS. Impact of a pay-for-performance program on low performing physicians. J. Healthc. Qual. 32(1), 13-22 (2010
55. Rosenthal M, Landon B. Pay for performance in commercial HMOs. N. Engl. J. Med. 355(18), 1895-1902 (2006
56. Hahn J, Morgan P, Stockdale H, Stone J. Medicare Provisions in PPACA (PL 111- 148). Congressional Research Service
57. Rosenthal MB, Landon BE, Howitt K, Song HR, Epstein AM Climbing up the pay-for-performance learning curve: Where are the early adopters now? Health Aff. 26(6), 1674-1682 (2007
58. Siegel RD, Clauser SB, Lynn JM. National Collaborative to Improve Oncology Practice: The National Cancer Institute Community Cancer Centers Program Quality Oncology Practice Initiative Experience. J. Oncol. Pract. 5(6), 276-281 (2009
59. National Cancer Policy Board. Ensuring Quality Cancer Care. National Academy Press. Washington, DC, USA (1999
60. Desch CE, McNiff KK, Schneider EC et al. American Society of Clinical Oncology/ National Comprehensive Cancer Network Quality Measures. J. Clin. Oncol. 26(21), 3631-3637 (2008
61. Newcomer LN, Perkins MR, Donelan SA. Tying payment incentives to quality measurement. J. Oncol. Pract. 9(3), 119-121 (2013
62. Chamie K, Saigal CS, Lai J et al. Quality of care in patients with bladder cancer. Cancer 118(5), 1412-1421 (2012
63. Lee TH, Bothe A, Steele GD. How Geisinger structures its physicians' compensation to support improvements in quality, efficiency, and volume. Health Aff. 31(9), 2068-2073 (2012
64. Mechanic RE. Opportunities and challenges for episode-based payment. N. Engl. J. Med. 365(9), 777-779 (2011
65. Stange KC, Nutting PA, Miller WL et al. Defining and measuring the patient-centered medical home. J. Gen. Intern. Med. 25(6), 601-612 (2010
66. McClellan M, McKethan AN, Lewis JL, Roski J, Fisher ES. A national strategy to put accountable care into practice. Health Aff. 29(5), 982-990 (2010
67. Mahan CE. Regulatory, policy and quality update for venous thromboembolism and stroke in United States hospitals. Thromb. Res. 130(4), 586-590 (2012
68. Sox HC. Comparative effectiveness research: A report from the Institute of Medicine. Ann. Intern. Med. 151(3), 203 (2009
69. Lyman GH. Comparative effectiveness research in oncology. Oncologist 18(6), 752-759 (2013
70. Roberts TG. Preparing for success with comparative effectiveness research. Oncologist 18(6), 655-657 (2013
71. Tunis SR, Benner J, McClellan M. Comparative effectiveness research: Policy context, methods development and research infrastructure. Stat. Med. 29(19), 1963-1976 (2010
72. Miksad RA, Schnipper L, Goldstein M. Does a statistically significant survival benefit of erlotinib plus gemcitabine for advanced pancreatic cancer translate into clinical significance and valuëJ. Clin. Oncol. 25(28), 4506-4507, author reply 4508 (2007
73. Montero AJ, Avancha K, Glück S, Lopes G. A cost-benefit analysis of bevacizumab in combination with paclitaxel in the first-line treatment of patients with metastatic breast cancer. Breast Cancer Res. Treat. 132(2), 747-751 (2012
74. Hornberger J, Reyes C, Lubeck D, Valente N. Economic evaluation of rituximab plus cyclophosphamide, vincristine and prednisolone for advanced follicular lymphoma. Leuk. Lymphoma 49(2), 227-236 (2008
75. Garrison LP, Lubeck D, Lalla D, Paton V, Dueck A, Perez EA. Cost-effectiveness analysis of trastuzumab in the adjuvant setting for treatment of HER2-positive breast cancer. Cancer 110(3), 489-498 (2007
76. Buxton MJ Economic evaluation and decision making in the UK. Pharmacoeconomics 4(11), 1133-1142 (2006
77. Nadler E Do oncologists believe new cancer drugs offer good valuëOncologist 11(2), 90-95 (2006
78. Gold MR, Sofaer S, Siegelberg T. Medicare and cost-effectiveness analysis: Time to ask the taxpayers. Health Aff. 26(5), 1399-1406 (2007
79. Jonsen A. Bentham in a box: Technology assessment and health care allocation. L. Med Health Care 14(3-4), 172-174 (1986
80. Brock DW. Ethical and value issues in insurance coverage for cancer treatment. Oncologist 15(Suppl. 1), 36-42 (2010
81. Temel JS, Greer JA, Muzikansky A et al. Early palliative care for patients with metastatic non-small-cell lung cancer. N. Engl. J. Med. 363(8), 733-742 (2010
82. Mack JW, Weeks JC, Wright AA, Block SD, Prigerson HG. End-of-life discussions, goal attainment, and distress at the end of life: Predictors and outcomes of receipt of care consistent with preferences. J. Clin. Oncol. 28(7), 1203-1208 (2010
83. Earle CC, Landrum MB, Souza JM, Neville BA, Weeks JC, Ayanian JZ. Aggressiveness of cancer care near the end of life: Is it a quality-of-care issuëJ. Clin. Oncol. 26(23), 3860-3866 (2008
84. Peppercorn JM, Smith TJ, Helft PR et al. American Society of Clinical Oncology statement: Toward individualized care for patients with advanced cancer. J. Clin. Oncol. 29(6), 755-760 (2011
85. Levy MH, Back A, Benedetti C et al. NCCN clinical practice guidelines in oncology: Palliative care. J. Natl Compr. Canc. Netw. 7(4), 436-473 (2009
86. Smith TJ, Hillner BE. Bending the cost curve in cancer care. N. Engl. J. Med. 364(21), 2060-2065 (2011
87. Neumann PJ, Palmer JA, Nadler E, Fang C, Ubel PA. Cancer therapy costs influence treatment: A national survey of oncologists. Health Aff. 29(1), 196-202 (2010
88. Meropol NJ, Schrag D, Smith TJ et al. American Society of Clinical Oncology guidance statement: The cost of cancer care. J. Clin. Oncol. 27(23), 3868-3874 (2009